[Intra-arterial administration of XXXX in the treatment of @entity157 . @entity1259 Study Group for @entity157 ].

@entity1 @entity1665 @entity632 @entity5 @entity1259 @entity236 @entity1726 @entity1575 @entity157 @entity1370
A group study was conducted to investigate the effect of intra-hepatic arterial administration of @entity1259 in the treatment of @entity157 ( @entity157 ). Sixty-four @entity1 were entered into the study. There were 51 males and 13 females, with an age range from 32 to 79 years, the average being 59.1 years. Fifty-four @entity1 had associated @entity1575 . @entity1259 at a dose of 60-90 mg/m2 was infused as a bolus into the hepatic artery 1 to 4 times (average 1.8) at an interval of 3 weeks to 3 months. @entity5 size was properly evaluated in 53 @entity1 . There were 1 CR, 7 PR, 7 MR, 27 NC, and 11 @entity1726 . Thus, the response rate (CR + PR) was 15.1%. Seventeen @entity1 are still alive 305 to 720 days (mean 505 days) after the initial treatment. The most common side effects of this drug were @entity236 , and @entity1665 . @entity1370 was negligible at the doses used in this study. A retrospective comparison of the present results with those for @entity1 treated by intra-arterial administration of @entity632 demonstrated that @entity1259 is more effective than @entity632 in terms of survival rate. The current study indicates that @entity1259 may be a promising alternative in the treatment of @entity157 . The appropriate dosage of the drug and the interval for infusion are to be elucidated. Also, the combination of @entity1259 with other cytostatic drugs is open for study.
